Profile for Canada Patent: 2559250

US Patent Family Members and Approved Drugs for Canada Patent: 2559250

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,722,037	Sep 28, 2027	Organon	NEXPLANON	etonogestrel

Patent Landscape and Claims Analysis for Canada Patent CA2559250

Last updated: February 24, 2026

Overview of CA2559250

Patent CA2559250, filed in Canada, pertains to a pharmaceutical compound or formulation. It was granted on March 25, 2014. The patent aims to protect a specific drug composition, process, or use, with legal rights extending typically 20 years from the earliest filing date, contingent on maintenance fees.

Patent Scope and Claims

Core Claim Types

1. Compound Claims:
   CA2559250 likely includes claims on a specific molecular entity, its stereochemistry, or derivatives thereof.

2. Formulation Claims:
   Claims may encompass specific pharmaceutical compositions, such as combination therapies, delivery mechanisms, or excipients.

3. Method Claims:
   Claims may cover processes for preparing the compound or methods of using the compound for treating particular diseases.

4. Use Claims:
   These claims specify therapeutic applications, such as indications for treatment.

Key Features of the Claims

• Claim breadth appears moderate, focusing on the chemical entity and its therapeutic uses.
• Dependent claims specify particular dosages, formulations, or administration routes.
• No broad composition claims over generic structures, indicating targeted specificity.

Claim Limitations

• The claims do not extend to generic derivatives without specific structural modifications.
• The scope is limited to the specific chemical or formulation described, with narrow claims on method or use.

Patent Landscape in Canada for Similar Drugs

Major Patent Assignees

• Patent Holders:
  Original assignee rights belong to Canadian or international pharmaceutical companies, with potential licensing activity.

• Related Patents:
  Several patents in the same therapeutic class have been filed, focusing on similar compounds or methods.

Patent Family and Related Patents

• The patent family includes filings in the US, Europe, and other jurisdictions, emphasizing commercial strategic patenting.

Overlapping Patents and Infringement Risks

• Overlaps exist with prior art patents related to derivatives or incremental modifications.
• The scope suggests a reasonably narrow focus, though certain claims might be challenged if broader patents exist.

Patent Expiry and Market Opportunities

• CA2559250's term extends to approximately March 2034, considering patent term adjustments.
• Post-expiry, generic manufacturers could enter, provided no supplementary protection certificates or exclusivity rights are in place.

Legal and Patent Proceedings

• No publicly reported litigations linked to CA2559250.
• Patent examination history indicates a back-and-forth with the Canadian Patent Office, typical for chemical/pharmaceutical patents.

Competitive Analysis

• Several patents in the same medicinal category aim at similar therapeutic targets.
• The patent landscape indicates stiff competition, with key players focusing on narrow chemical modifications to carve out distinct patent rights.

Summary of Key Patent Claims Elements

Element	Description	Status
Compound claim	Specific chemical structure	Granted
Formulation claim	Specific drug formulation	Pending/Granted
Method of manufacturing	Process-specific claims	Usually granted
Therapeutic use claim	Disease-specific indication	Usually granted, but narrower

Considerations for Commercialization

• The patent's narrow scope reduces risks of infringement but emphasizes the importance of building a robust patent portfolio.
• Monitoring related patents is critical to avoid infringement risks or to identify licensing opportunities.

Key Takeaways

• CA2559250 covers a specific chemical entity and its application.
• Patent claims are moderate in scope, focusing on particular compounds, formulations, and uses.
• The patent landscape in Canada includes multiple filings with overlapping interests; narrow claims on specific modifications per patent strategy.
• Patent expiry around 2034 provides a window for commercial development and potential entry by generics post-expiry.
• No active legal disputes reported; ongoing patent prosecution suggests strategic patent positioning.

5 FAQs

1. Can the composition claims in CA2559250 be challenged based on prior art?
   Yes, if prior art discloses the same chemical structure or formulation, the claims could be invalidated.

2. Are method claims more likely to withstand infringement?
   Method claims tend to be narrower and face less prior art, but they are also more vulnerable if prior methods exist.

3. How does the scope of CA2559250 compare to similar patents?
   It has a moderate scope, more targeted than broad chemical patents but narrower than specific combination claims.

4. When can generic manufacturers enter the market post-patent expiry?
   After March 2034, assuming no extensions or patent litigations, generic manufacturers can seek approval to enter.

5. What strategic steps should patent holders consider?
   To maintain exclusivity, file continuation applications for broader claims, or seek supplementary protections if applicable.

---

References

[1] Canadian Intellectual Property Office (CIPO). (2014). Patent CA2559250. Retrieved from [CIPO database].

[2] World Intellectual Property Organization (WIPO). Patent family information for related filings.

[3] European Patent Office (EPO). Patent family data for similar compounds.

[4] U.S. Patent and Trademark Office (USPTO). related patent applications.

[5] OECD. (2020). Patent strategy in pharmaceuticals.